SAB BIO

SAB BIO

Biotechnology Research

Miami, FL 2,624 followers

We're developing a disease-modifying immunotherapy aimed at delaying the onset and progression of type 1 diabetes

About us

A clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing fully-human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D)

Industry
Biotechnology Research
Company size
51-200 employees
Headquarters
Miami, FL
Type
Public Company

Locations

Employees at SAB BIO

Updates

Similar pages

Funding